Pieris achieves second milestone payment under anticalin therapeutic collaboration with Daiichi

Various in vitro and in vivo studies validated a range of Anticalin targeted protein drug candidates designed to bind to a Daiichi’s target and thus an undisclosed payment is triggered.

Daiichi will now take up further responsibility to advance the program.

Pieris CEO Stephen Yoder said, "Pieris continues to demonstrate the advantages of Anticalins through the success of our partnerships, in particular our ability to rapidly design differentiated targeted therapeutics that overcome specific hurdles encountered by both mAbs and small molecules."

The human lipocalin derived therapeutic proteins named Anticalin are rationally engineered to overcome the pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms.

According to the agreement signed between the two companies in 2011, Daiichi will have exclusive global marketing rights for Anticalin proteins resulting from the collaboration.